Literature DB >> 25083425

Abnormality of pl6/p38MAPK/p53/Wipl pathway in papillary thyroid cancer.

Dehua Yang1, Hao Zhang1, Xinhua Hu1, Shijie Xin1, Zhiquan Duan1.   

Abstract

OBJECTIVE: To investigate the expression of the pl6/p38MAPK/p53/Wipl pathway in patients with papillary thyroid cancer (PTC) and its clinical significance.
METHODS: The protein expressions of Wipl, p53, p38MAPK, and p16 in 70 cases of PTC tissues and 20 cases of normal thyroid tissues were detected by immunohistochemical staining. The correlations of Wipl protein high-expression with p53, p38MAPK, and pl6 protein expressions were analyzed.
RESULTS: The high-expression rate of Wipl protein in the PTC tissue was 64.3% (45/70), which was significantly different than that in normal thyroid tissue (0/20) (P<0.01). There were no significant differences between the paired groups in terms of age, gender, tumor size, and lymph node metastasis (all P>0.05). The Wipl protein high-expression was negatively correlated with the expressions of p38MAPK, p53 and pl6 (r value was -0.620, 0.356 and 0.550, respectively, and all P<0.01).
CONCLUSIONS: The pl6/p38MAPK/p53/Wipl pathway is abnormal in PTC, and this abnormality may possibly be associated with the aberrantly up-regulated Wipl, which can induce inhibition of p38MAPK, p53 and pi6.

Entities:  

Keywords:  Thyroid neoplasms; carcinoma, papillary; immunohistochemistry; wild-type p53-induced phosphatase 1

Year:  2012        PMID: 25083425      PMCID: PMC4115712          DOI: 10.3978/j.issn.2227-684X.2012.04.01

Source DB:  PubMed          Journal:  Gland Surg        ISSN: 2227-684X


  18 in total

1.  Oncogenic properties of PPM1D located within a breast cancer amplification epicenter at 17q23.

Authors:  Jing Li; Ying Yang; Yue Peng; Richard J Austin; Winfried G van Eyndhoven; Ken C Q Nguyen; Tim Gabriele; Mila E McCurrach; Jeffrey R Marks; Timothy Hoey; Scott W Lowe; Scott Powers
Journal:  Nat Genet       Date:  2002-05-20       Impact factor: 38.330

2.  The oncogenic phosphatase WIP1 negatively regulates nucleotide excision repair.

Authors:  Thuy-Ai Nguyen; Scott D Slattery; Sung-Hwan Moon; Yolanda F Darlington; Xiongbin Lu; Lawrence A Donehower
Journal:  DNA Repair (Amst)       Date:  2010-05-06

3.  Increasing incidence of thyroid cancer in Shanghai, China, 1983-2007.

Authors:  Youxin Wang; Wei Wang
Journal:  Asia Pac J Public Health       Date:  2012-02-16       Impact factor: 1.399

4.  Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions.

Authors:  Vassilis G Gorgoulis; Leandros-Vassilios F Vassiliou; Panagiotis Karakaidos; Panayotis Zacharatos; Athanassios Kotsinas; Triantafillos Liloglou; Monica Venere; Richard A Ditullio; Nikolaos G Kastrinakis; Brynn Levy; Dimitris Kletsas; Akihiro Yoneta; Meenhard Herlyn; Christos Kittas; Thanos D Halazonetis
Journal:  Nature       Date:  2005-04-14       Impact factor: 49.962

5.  DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis.

Authors:  Jirina Bartkova; Zuzana Horejsí; Karen Koed; Alwin Krämer; Frederic Tort; Karsten Zieger; Per Guldberg; Maxwell Sehested; Jahn M Nesland; Claudia Lukas; Torben Ørntoft; Jiri Lukas; Jiri Bartek
Journal:  Nature       Date:  2005-04-14       Impact factor: 49.962

6.  Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity.

Authors:  Dmitry V Bulavin; Oleg N Demidov; Shin'ichi Saito; Paivikki Kauraniemi; Crissy Phillips; Sally A Amundson; Concetta Ambrosino; Guido Sauter; Angel R Nebreda; Carl W Anderson; Anne Kallioniemi; Albert J Fornace; Ettore Appella
Journal:  Nat Genet       Date:  2002-05-20       Impact factor: 38.330

7.  Development of a substrate-based cyclic phosphopeptide inhibitor of protein phosphatase 2Cdelta, Wip1.

Authors:  Hiroshi Yamaguchi; Stewart R Durell; Hanqiao Feng; Yawen Bai; Carl W Anderson; Ettore Appella
Journal:  Biochemistry       Date:  2006-11-07       Impact factor: 3.162

Review 8.  WIP1 phosphatase at the crossroads of cancer and aging.

Authors:  Xavier Le Guezennec; Dmitry V Bulavin
Journal:  Trends Biochem Sci       Date:  2009-10-29       Impact factor: 13.807

9.  Increased wild-type p53-induced phosphatase 1 (Wip1 or PPM1D) expression correlated with downregulation of checkpoint kinase 2 in human gastric carcinoma.

Authors:  Takeichi Fuku; Shuho Semba; Hirokazu Yutori; Hiroshi Yokozaki
Journal:  Pathol Int       Date:  2007-09       Impact factor: 2.534

Review 10.  An oncogene-induced DNA damage model for cancer development.

Authors:  Thanos D Halazonetis; Vassilis G Gorgoulis; Jiri Bartek
Journal:  Science       Date:  2008-03-07       Impact factor: 47.728

View more
  5 in total

1.  Erratum to abnormality of p16/p38MAPK/p53/Wipl pathway in papillary thyroid cancer.

Authors: 
Journal:  Gland Surg       Date:  2015-12

Review 2.  Wip1 phosphatase in breast cancer.

Authors:  A Emelyanov; D V Bulavin
Journal:  Oncogene       Date:  2014-11-10       Impact factor: 9.867

Review 3.  Looking at Thyroid Cancer from the Tumor-Suppressor Genes Point of View.

Authors:  Sadegh Rajabi; Catherine Alix-Panabières; Arshia Sharbatdar Alaei; Raziyeh Abooshahab; Heewa Shakib; Mohammad Reza Ashrafi
Journal:  Cancers (Basel)       Date:  2022-05-17       Impact factor: 6.575

Review 4.  New Insights in Thyroid Cancer and p53 Family Proteins.

Authors:  Livia Manzella; Stefania Stella; Maria Stella Pennisi; Elena Tirrò; Michele Massimino; Chiara Romano; Adriana Puma; Martina Tavarelli; Paolo Vigneri
Journal:  Int J Mol Sci       Date:  2017-06-21       Impact factor: 5.923

5.  Clinical significance of Wip1 overexpression and its association with the p38MAPK/p53/p16 pathway in NSCLC.

Authors:  Shize Yang; Siyuan Dong; Xiaohan Qu; Xinwen Zhong; Qigang Zhang
Journal:  Mol Med Rep       Date:  2016-12-13       Impact factor: 2.952

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.